Cefiderocol in the Successful Treatment of Complicated Hospital-Acquired K. pneumoniae NDM, OXA48 Intraabdominal

Ignacy Tarski1, Jakub Śmiechowicz2, Wiesława Duszyńska2

  • 1Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland.

PubMed
Abstract

Insights

Cefiderocol monotherapy effectively treated a patient with septic shock caused by multidrug-resistant Klebsiella pneumoniae (MDR/XDR KP). This offers a promising option for difficult-to-treat infections.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Pharmacology

Background:

  • Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Klebsiella pneumoniae present significant therapeutic challenges.
  • Limited effective antibiotic options exist for severe MDR/XDR KP infections.

Observation:

  • A 72-year-old female patient with sepsis due to KP NDM, OXA 48 developed septic shock post-kidney transplant surgery.
  • Initial broad-spectrum antibiotics were ineffective; serial cultures revealed persistent KP with limited susceptibility.
  • The patient's condition showed minimal improvement until cefiderocol monotherapy was initiated.

Findings:

  • Cefiderocol monotherapy, initiated on day 37, led to decreased inflammatory markers (CRP, PCT) and significant clinical improvement within 4 days.
  • Combination therapies including meropenem/vaborbactam, ceftazidime/avibactam, aztreonam, and colistin provided survival but not full recovery.

Implications:

  • Cefiderocol monotherapy demonstrates high efficacy in treating severe infections caused by extensively drug-resistant Klebsiella pneumoniae.
  • This case highlights the critical role of novel antibiotics like cefiderocol in managing challenging Gram-negative bacterial infections.
  • Early identification of pathogen susceptibility and tailored antibiotic selection are crucial for patient outcomes.